Quantum Cyber N.V. Expands ATM Program to $100M, CFO Transitions to Consulting Role
QUCY is trading near its 52-week low of $0.34 (6.8% above the low) on light trading volume (0.3× avg).
Summary
Quantum Cyber N.V. significantly increased its At-The-Market (ATM) equity offering program to $100 million, a substantial potential dilution relative to its market cap, while its CFO transitioned to a consulting agreement with a $20,000 monthly retainer.
Key Events · Financing and Capital Events · QUCY
-
ATM Program Expanded to $100 Million
The company amended its Equity Distribution Agreement with Maxim Group LLC, increasing the aggregate offering amount of ordinary shares that can be sold from $10 million to $100 million. This is an update to an existing program established on October 3, 2025, and represents a potential dilution significantly exceeding the company's current market capitalization.
-
CFO Transitions to Consulting Agreement
William Caragol, the Chief Financial Officer, entered into a consulting agreement effective April 22, 2026, to continue providing financial and accounting services. He will receive a monthly retainer of $20,000, with potential for stock or option grants. This transition marks a change in executive structure and introduces a significant ongoing operational cost relative to the company's size.
Analysis · QUCY · Life Sciences
Quantum Cyber N.V. has significantly expanded its At-The-Market (ATM) equity program to $100 million, a move that represents an extremely high potential for dilution given the company's current market capitalization. This follows a recent highly dilutive $6 million private placement and the company's prior disclosure of substantial doubt about its ability to continue as a going concern. The massive increase in the ATM program signals an urgent need for capital, likely at terms highly unfavorable to existing shareholders. Additionally, the company's CFO has transitioned to a consulting agreement with a monthly retainer of $20,000, which is a notable expense for a company of this size and financial standing, raising questions about executive stability and operational costs.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QUCY was trading at $0.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $0.34 to $2.64. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.